Outcome

The outcomes of this study indicate that hyperbaric oxygen therapy (HBOT) at 1.5 atmospheres absolute pressure may effectively alleviate symptoms of hypoxemia in patients with severe COVID-19 pneumonia. After just one treatment patients experienced immediate relief from dyspnea and shortness of breath with further significant improvement noted after a week.

Introduction

The COVID-19 pandemic has posed significant challenges to global healthcare systems particularly in managing severe pneumonia cases characterized by hypoxemia. Hyperbaric Oxygen Therapy (HBOT) has been proposed as a potential therapeutic intervention to alleviate the symptoms of hypoxemia in such patients. This study explores the effects of HBOT at 1.5 atmospheres absolute pressure on two patients with severe COVID-19 pneumonia. Following daily treatments for one week both patients experienced immediate relief from dyspnea and shortness of breath as well as substantial improvements in respiratory rate oxygen saturation and overall lung function. Moreover chest CT scans indicated a reduction in pulmonary inflammation pointing to the potential benefits of HBOT. These preliminary findings suggest that HBOT could be an effective tool in treating severe COVID-19 pneumonia though further research through randomized clinical trials is necessary to validate these observations.

Results

This study examined the impact of hyperbaric oxygen therapy (HBOT) on two male patients aged 57 and 64 suffering from severe COVID-19 pneumonia. Both patients presented with significant symptoms including shortness of breath and low oxygen saturation. Each received HBOT at 1.5 atmospheres absolute pressure administered once daily over a span of seven days.

After the initial HBOT session both patients exhibited considerable improvement. Specifically symptoms of dyspnea and shortness of breath were markedly alleviated. Their respiratory rates showed a daily decrease indicating progressive recovery. Importantly neither patient progressed to a critically ill state throughout the treatment period.

Key physiological improvements were recorded consistently. Oxygen levels as indicated by SpO2 and the P/F ratio a marker of lung function increased each day. Additionally immune function assessed via lymphocyte count showed a gradual and steady enhancement. The patients also exhibited improvements in indicators of peripheral circulation disorders measured by D-dimer levels and liver function denoted by serum cholinesterase measurements.

Subsequent chest CT scans supported these clinical improvements revealing notable reductions in pulmonary inflammation. These findings suggest that HBOT may be a beneficial adjunctive therapy for managing severe COVID-19 pneumonia offering immediate and sustained relief from critical respiratory symptoms.

The promising outcomes observed in these case reports justify further exploration of HBOT through larger randomized clinical trials to confirm its efficacy and safety in treating severe COVID-19 pneumonia.

Conclusion

In summary this study presents encouraging evidence suggesting that hyperbaric oxygen therapy (HBOT) at 1.5 atmospheres absolute pressure may effectively alleviate symptoms of hypoxemia in patients with severe COVID-19 pneumonia. Both patients demonstrated immediate and significant improvement in dyspnea and shortness of breath after the first treatment session with sustained progress over a week of daily therapy. Enhancements in respiratory rate oxygen saturation lung function (P/F ratio) immune function (lymphocyte count) and reduction of inflammation were observed.

These preliminary findings underscore the potential of HBOT as a beneficial intervention for severe COVID-19 pneumonia offering a novel approach to mitigating respiratory distress and improving overall pulmonary health. The results advocate for the exploration of HBOT in larger randomized clinical trials to verify these outcomes and to better understand the scope of its efficacy and safety. Such future research could solidify HBOT as a valuable treatment modality in the ongoing battle against severe COVID-19 pneumonia and potentially other related conditions.